Today: 27 June 2026
Browse Category

NYSEA:YCBD 15 December 2025

cbdMD (YCBD) Stock News Today (Dec. 15, 2025): Why Shares Are Volatile, What the Latest Filings Say, and the Updated YCBD Stock Forecast

cbdMD (YCBD) Stock News Today (Dec. 15, 2025): Why Shares Are Volatile, What the Latest Filings Say, and the Updated YCBD Stock Forecast

cbdMD shares surged after the company regained full NYSE American compliance, with the “.BC” flag removed as of December 8. Preliminary FY2025 results show net sales steady near $19.2 million and net loss narrowing to $1.9–$2.1 million. Broader sector momentum followed reports of potential cannabis rescheduling under a Trump administration.
15 December 2025

Stock Market Today

  • Dollar Drops on Lower Crude Prices, Easing Fed Rate-Hike Fears
    June 27, 2026, 10:22 AM EDT. The U.S. dollar slipped 0.07% on Friday as WTI crude oil prices fell over 3% to a four-month low, reducing inflation concerns and lessening expectations of aggressive Federal Reserve interest rate hikes. The University of Michigan's June consumer sentiment index came in weaker than expected, pressuring the dollar further. However, hawkish comments from Minneapolis Fed President Neel Kashkari, expressing inflation concerns and support for a rate increase, helped the dollar partially recover. Euro gained 0.12%, bolstered by the weaker dollar and Europe's energy import reliance benefiting from lower oil prices. The yen strengthened modestly against the dollar following higher-than-expected Tokyo CPI inflation and a 4% Nikkei drop, boosting safe-haven demand despite concerns over Bank of Japan's slow policy normalization.

Latest articles

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week

27 June 2026
Moderna soared 12.6% Friday on heavy volume after unveiling new in vivo CAR-T pipeline plans, closing at $67.27—52% above the mean analyst target but still 14.5% below Piper Sandler’s new $77 target. The rally followed Science Day updates, even as analysts note the main new asset is preclinical and cash burn continues, with $7.5B cash at March-end and a projected $3B R&D spend for 2026.
Go toTop